BioTime, Inc. (BTX)
-NYSE MKT 4.23 
0.04(0.95%) 4:02PM EDT|After Hours
:
4.23 0.00 (0.00%) 4:31PM EDT
| Prev Close: | 4.19 |
|---|
| Open: | 4.21 |
|---|
| Bid: | 3.40 x 100 |
|---|
| Ask: | 5.00 x 1200 |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | 1.06 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 4.20 - 4.34 |
|---|
| 52wk Range: | 2.67 - 5.07 |
|---|
| Volume: | 170,813 |
|---|
| Avg Vol (3m): | 145,251 |
|---|
| Market Cap: | 222.29M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.49 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- July Options Now Available For BioTime (BTX)at TheStreet(Mon, May 20)
- BioTime CEO Dr. Michael West to Present at USC Minisymposium: Musculoskeletal Development and RepairBusiness Wire(Mon, May 20)
- BIOTIME INC FinancialsEDGAR Online Financials(Fri, May 17)
- BIOTIME INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and ExhEDGAR Online(Tue, May 14)
- BioTime Appoints Franklin Berger to Board of DirectorsBusiness Wire(Tue, May 14)
- BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.5 Million Grant from Israel’s Office of the Chief ScientistBusiness Wire(Mon, May 13)
- BIOTIME INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Mon, May 13)
- BioTime Announces First Quarter 2013 Financial Results and Recent Corporate AccomplishmentsBusiness Wire(Fri, May 10)
- BIOTIME INC Files SEC form 8-K, Results of Operations and Financial ConditionEDGAR Online(Fri, May 10)
- BIOTIME INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- PDL BioPharma Announces First Quarter 2013 Financial ResultsPR Newswire(Thu, May 9)
- BioTime and Subsidiary LifeMap Sciences Announce Release of Enhanced LifeMap BioReagents™ Portal Offering Additional PureStem™ Human Progenitor Cells Including Those for Diabetes ResearchBusiness Wire(Tue, May 7)
- PDL BioPharma Appoints Peter Garcia as Chief Financial OfficerPR Newswire(Tue, Apr 30)
- CFO Moves: Time Warner Cable, BioTime, BluePhoenixat The Wall Street Journal(Tue, Apr 30)
- LifeMap Sciences, a Subsidiary of BioTime, Announces Release of GeneCards® Version 3.10Business Wire(Tue, Apr 30)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 56.79 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(0-00-31)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
BioTime, Inc., a biotechnology company, focuses on regenerative medicine and blood plasma volume expanders. The company primarily focuses on regenerative medicine, which refers to therapies based on human embryonic stem cell and induced pluripoten...
View More